Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease. A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute and the Alzheimer's Association addressed challenges in designing clinical trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.

Original publication

DOI

10.1586/14737175.2015.996551

Type

Journal article

Journal

Expert Rev Neurother

Publication Date

03/2015

Volume

15

Pages

327 - 333

Keywords

Alzheimer’ disease, co-development, collaboration, combination therapy, novel therapy, Alzheimer Disease, Animals, Clinical Trials as Topic, Disease Models, Animal, Drug Therapy, Combination, Humans, Information Dissemination, Models, Theoretical